Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer
Open Access
- 4 January 2019
- Vol. 11 (1), 42
- https://doi.org/10.3390/cancers11010042
Abstract
Genomic studies performed through liquid biopsies widely elucidated the evolutionary trajectory of RAS mutant clones under the selective pressure of EGFR inhibitors in patients with wild type RAS primary colorectal tumors. Similarly, the disappearance of RAS mutant clones in plasma has been more recently reported in some patients with primary RAS mutant cancers, supporting for the first time an unexpected negative selection of RAS mutations during the clonal evolution of mCRC. To date, the extent of conversion to RAS wild type disease at the time of progression has not been clarified yet. As a proof of concept, we prospectively enrolled mCRC patients progressing under anti-VEGF based treatments. Idylla™ system was used to screen RAS mutations in plasma and the wild type status of RAS was further confirmed through IT-PGM (Ion Torrent Personal Genome Machine) sequencing. RAS was found mutant in 55% of cases, retaining the same plasma mutation as in the primary tumor at diagnosis, while it was found wild-type in 45%. Four patients testing negative for RAS mutations in plasma at the time of progression of disease (PD) were considered eligible for treatment with EGFR inhibitors and treated accordingly, achieving a clinical benefit. We here propose a hypothetical algorithm that accounts for the transient disappearance of RAS mutant clones over time, which might extend the continuum of care of mutant RAS colorectal cancer patients through the delivery of a further line of therapy.This publication has 15 references indexed in Scilit:
- Thalidomide: Rebirth of a Gestational Antiemetic?Journal of Clinical Oncology, 2017
- RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trialAnnals of Oncology, 2017
- Integrating liquid biopsies into the management of cancerNature Reviews Clinical Oncology, 2017
- Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemiaProceedings of the National Academy of Sciences of the United States of America, 2016
- Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemiaProceedings of the National Academy of Sciences of the United States of America, 2016
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnnals of Oncology, 2016
- Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?Critical Reviews in Oncology/Hematology, 2016
- Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patientsNature Medicine, 2015
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal CancerJournal of Clinical Oncology, 2015
- Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR TherapyClinical Cancer Research, 2015